ZNF326 as a potential prognostic and predictive biomarker in stage II colorectal cancer.

ABSTRACT:

Background

Adjuvant chemotherapy is considered for stage II colorectal cancer (CRC) patients with poor prognostic risk factors. However, current stratification algorithms are still insufficient to identify high-risk patients.

Methods

We conducted a screening strategy to define ZNF326 based on quantitative proteomics in 11 paired CRC patients selected by a nested case-control design, and tested the association between ZNF326 expression level with the prognosis of stage II CRC patients and the benefit from adjuvant chemotherapy in public datasets; further investigation was conducted through subgroup analyses.

Results

We found that low ZNF326 expression was significantly associated with a lower 5-year overall survival (OS) rate among stage II patients in bo

SUBMITTER: Pu H 

PROVIDER: S-EPMC10932666 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature